SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle (ORCL) is trending after reporting strong earnings that beat estimates and raising its FY27 revenue guidance, driven by explosive cloud infrastructure growth and a massive increase in Remaining Performance Obligations from AI contracts. The community is actively discussing whether these robust results, which highlight significant customer prepayments for AI capacity, will finally overcome prior concerns about the company's capital expenditures.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment (AVAV) is trending after a Q3 earnings miss and news of a Space Force contract termination caused a sharp sell-off, with a new Army contract and record backlog leading many to debate if the market has overreacted amidst strong demand for drone technology.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending after reporting surprisingly strong recent results, which defied expectations by showing a return to profitability and revenue growth. This has sparked a heated debate among investors, with bulls hailing a fundamental turnaround and potential short squeeze, while skeptics view the surge as unsustainable manipulation given the company's historical challenges and perceived declining relevance.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace (FLY) is trending amid intense community discussion surrounding its upcoming rocket launch, where anticipation for success clashes with frustration over repeated delays, while investors also consider its long-term potential in the burgeoning space and defense sector, including "Golden Dome" contracts.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and providing strong delivery guidance, leading to multiple analyst upgrades and fueling community excitement about a potential short squeeze and a long-awaited rebound for the EV innovator, especially with its advanced in-house chip development.

The Beachbody Co., Inc. operates as a health and wellness company. It offers holistic health and wellness platforms. The company's product offerings include digital subscriptions, nutritional products, and connected fitness products. Digital subscriptions include Beachbody On Demand (BOD) and Openfit. The subscriptions are renewed on a monthly, quarterly, or annual basis and include unlimited access to a library of live and on-demand fitness and nutrition content. Nutritional products include Shakeology, Beachbody Performance supplements, BEACHBARs, and others. Connected fitness products include The Beachbody Bike (also known as Myx), which is equipped with a swivel touch screen that enables users to engage with content beyond the indoor cycling experience and encourages broader cross-training, incorporating resistance training and yoga for a more holistic fitness experience and healthier results. The company was founded by Carl Daikeler and Jon Congdon in 1998 and is headquartered in El Segundo, CA.

Beachbody Company Inc (The) - Ordinary Shares - Class A

BODI is trending as its recent financial results, showing positive adjusted EBITDA and projected positive cash flow, fuel speculation of a turnaround for the fitness company. This has ignited a split in the community, with some anticipating a recovery while long-term investors remain deeply wary of past dilution and management's promises.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

SIGA Technologies Inc

Investors are buzzing about SIGA Technologies following its recent Q4 earnings, with community discussions centering on the company's robust cash reserves, the likelihood of a special dividend, and the highly anticipated new BARDA contract for TPOXX, solidifying its role in biodefense amidst ongoing global health concerns.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics is trending as its March 16 PDUFA date approaches for the dry eye treatment Reproxalap, where community sentiment is sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections, a quiet review beyond the labeling milestone, and a key executive's departure.

Franco-Nevada Corp. engages in the management of gold-focused royalties and streams portfolio. It provides investors with gold price and exploration optionality while limiting exposure to many of the risks of operating companies. The company was founded in 1983 and is headquartered in Toronto, Canada.

Franco-Nevada Corporation

FNV is attracting buzz after its strong Q4 earnings beat, increased dividend, and optimistic 2026 guidance that notably excludes a Cobre Panama restart, leading the community to view any potential return of the mine as pure upside in the current booming gold market.

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

vTv Therapeutics Inc - Ordinary Shares - Class A

vTv Therapeutics is trending due to the FDA lifting the clinical hold on its cadisegliatin Type 1 diabetes program, a shortened Phase 3 trial, and an $80 million private placement. The community is keenly focused on the stock's very low float and breakthrough status, anticipating significant upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen

Wall Street Zen upgraded Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short Interest

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Average Rating of "Moderate Buy" by Brokerages

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company...

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research

BTIG Research boosted their price objective on shares of Acumen Pharmaceuticals from $4.00 to $7.00 and gave the company a "buy" rating in a research note on Tuesday...

Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells $12,536.16 in Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of...

Insider Selling: Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Sells 6,888 Shares of Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of Acumen Pharmaceuticals stock in a transaction dated Thursday, January 8th. The shares were sold at an...

Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Sells $14,820.26 in Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 8,143 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average...

Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,941 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,941 shares of the business's stock in a transaction that occurred on Friday, January 9th. The stock was...

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) have earned an average rating of "Moderate Buy" from the five research firms that are presently covering the company...

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.

Acumen Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

ABOS
Acumen Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ABOS News

ABOSAcumen Pharmaceuticals Inc